Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.30 |
| ▸ | UGT2B17 | O75795 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055338 | 0.88 | EPAS1 (0.37) | ACHENOS3NOS1NOS2 | |
| SCHEMBL10286119 | 0.81 | UGT2B17 (0.38) | ACHENOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL14884984 | 0.80 | ACHE (0.39) | ACHENOS3NOS1NOS2 | |
| SCHEMBL30667065 | 0.80 | ACHE (0.39) | ACHENOS3NOS1NOS2 | |
| SCHEMBL10286199 | 0.76 | ADRA1A (0.39) | ACHE | |
| SCHEMBL10286141 | 0.76 | HTR2A (0.38) | ACHENOS3NOS1NOS2TSHR | |
| SCHEMBL8784135 | 0.76 | UGT2B17 (0.42) | ACHENOS3NOS1NOS2KCNH2 | |
| SCHEMBL30640696 | 0.76 | UGT2B17 (0.42) | ACHENOS3NOS1NOS2KCNH2 | |
| SCHEMBL10287354 | 0.76 | ACHE (0.41) | ACHENOS3NOS1NOS2BRD3 | |
| SCHEMBL10286117 | 0.75 | ACHE (0.42) | ACHEBRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | MSR1, DDT, MPO | ACHE 660/4885NOS3 239/4885NOS1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.